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High rates of aerobic glycolysis represent a key mechanism by which endometrial cancer cells consume
glucose as its primary energy source. The up-regulated glycolytic pathway is a common therapeutic target
whose inhibition has implications for anti-tumor activity in cancer cells. The present study was aimed at
evaluating the potential of a novel lactate dehydrogenase (LDH) inhibitor, Galloflavin, as a therapeutic agent
for endometrial cancer. Our results revealed that Galloflavin effectively inhibited cell growth in endometrial
cancer cell lines and primary cultures of human endometrial cancer through its involvement in multiple
signaling pathways that regulate metabolism, cell cycle, apoptosis, cell stress and metastasis.
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Galloflavin (GF), which is synthesized from gallic acid,
is a new lactate dehydrogenase inhibitor that inhibits
both the A and B isoforms of LDH [1]. By serving as a
competitive inhibitor with NADH for LDH, GF has
been shown to disrupt aerobic glycolysis and decrease
cell viability effectively across many cancer cell types,
including breast, colon and liver cancers as well as
Burkitt lymphoma [2-4]. To investigate the effect of GF
on endometrial cancer cell growth, we utilized the
Ishikawa and ECC-1 cells exhibiting high rates of gly-
colysis to identify the potential of GF. GF significantly
reduced LDHA activity, inhibited cell proliferation and
reduced colony formation in a dose dependent manner
(Figure 1, Additional file 1). The IC50 values for the
ECC-1 and Ishikawa cells were 25 uM and 43 uM after
72 hours of treatment, respectively. We next confirmed* Correspondence:
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unless otherwise stated.that GF was responsible for the activation of the mito-
chondrial apoptosis pathway, accompanied by an in-
crease in cleaved caspase3 and a decrease in MCL-1 and
BCL-2 protein expression (Additional file 2: Figure S1). Cell
cycle analysis showed minimal G1 phase arrest in the ECC-
1 cells and G2 arrest in Ishikawa cells after 24 hours of
treatment (Additional file 3: Figure S2), thus, suggesting that
GF induces cell cycle changes by altering different check-
points in different endometrial cancer cells. After treatment
with GF for 24 hours, both cell lines had a reduced ability to
adhere to laminin-1 as well as decreased migratory capacity
as evaluated by a transwell assay. In addition, E–cadherin
increased while Slug proteins decreased after treatment with
GF (Additional file 4: Figure S3). GF was also shown to
increase reactive oxygen species (ROS) and mitochondrial
DNA damage after 24 hours of treatment (Additional file 5:
Figure S4), indicating that an increase in ROS production
and mitochondrial DNA damage might also be involved in
the anti-tumorigenic effects of GF in endometrial cancer
cells.is is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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Figure 1 Galloflavin inhibited cell proliferation in the ECC-1 and Ishikawa cells. The ECC-1 and Ishikawa cell lines were cultured in 96-well plates for
24 hours and treated with GF at the indicated doses for 72 hours. Cell proliferation was assessed with MTT assay (A). The cells were cultured in 6 well plates
for 24 hours, treated with GF for 48 hours and then cultured for an additional 10 days. Colony formation assay was assessed (B, C). The effect of GF on LDHA
activity level was examined using a LDHA activity assay kit (D). GF decreased LDHA activity in the endometrial cancer cells after 16 hours of treatment.
(* < 0.05).
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chondrial oxidative phosphorylation (OXPHOS) cap-
acity to rapidly switch from glycolysis to OXPHOS
during carcinogenesis and cell energy stress [5,6]. The
point of balance between glycolysis and mitochondrial
OXPHOS fluctuates depending on changes in the cancer
cells microenvironment. Inhibition of LDHA activity by
GF resulted in a decreased rate of glucose uptake and
ATP production, with subsequent increased pyruvate de-
hydrogenase (PDH) protein expression and production of
pyruvate (Additional file 6: Figure S5). These findings con-
firm a direct effect of GF on the glucose metabolism by
impairing cytosolic glycolysis in the endometrial cancer
cells. Since glycolysis and OXPHOS are tightly coupled
processes [7], we noted that GF increased glutaminase
protein expression, and enhanced Krebs cycle activity, by
increasing the production of malate, another Krebs cycle
intermediate, after 16 hours of treatment (Additional file
7: Figure S6). GF was effective in inhibition of cellproliferation in 6 of the 8 primary cultures of endometrial
cancer with IC50 values ranging from 20-53 uM. A linear
regression model showed the level of LDHA protein but
not c-Myc was related to the sensitivity to GF in primary
cultures and endometrial cancer cell lines (Figure 2).
Moreover, we found that GF decreased c-Myc expression
in a dose-dependent manner after 24 hours of treatment.
Given that c-Myc transcriptionally induces expression and
activity of LDHA [8], the inhibition of c-Myc by JQ1 (a c-
Myc inhibitor) synergistically increased the inhibitory
effects of GF at different concentrations in GF-sensitive
and GF-resistant cells (Additional file 7: Figure S6).
These results suggest a causal link between GF treat-
ment and down-regulation of c-Myc expression in
endometrial cancer cells (Additional file 8: Figure S7).
In conclusion, our study indicated that targeted inhib-
ition of LDH by GF has promising anti-tumor activity in
endometrial cancer cell lines and primary cultures of




Figure 2 Galloflavin inhibited cell proliferation in primary cultures of endometrial cancer. Eight primary cell cultures of endometrial cancer
were cultured in 96 well plates and treated with GF as indicated doses for 72 hours. Cell proliferation was assessed by MTT assay (A). LDHA
protein expression in the primary cell cultures was detected by Western blotting (B). Eight established endometrial cancer and ovarian cancer cell
lines were cultured in 96 well plates, and treated with GF for 72 hours. Cell proliferation was assessed by MTT assay (C). LDHA and c-Myc protein
expression in the eight cell lines was detected by Western blotting (D). The relationship of LDHA and c-Myc protein expression and cell response
to GF was assessed by Pearson correlation. The results showed a significant correlation between LDHA expression and cell growth inhibition by
GF (Pearson r =0.77026; p = 0.0005; n = 16) (E). There was no significant correlation between c-Myc protein expression and cell sensitivity to GF
(F) (* < 0.05).
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cell proliferation, invasion, and glycolytic metabolism
while promoting cell stress and apoptosis in endometrialcancer cells. These findings provide a molecular basis for
the use of LDH inhibitors in the treatment of endometrial
cancer.
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Additional file 1: Material and Methods.
Additional file 2: Figure S1. Galloflavin induced apoptosis in ECC-1 and
Ishikawa cells. The ECC-1 (A, C) and Ishikawa cells (B, D) were cultured for
24 hours and treated with GF at different concentrations overnight. Apoptosis
was examined by an Annexin V assay using Cellometer. The effect of GF on
BCL-2, MCL-1, caspase-3 and cleaved caspase-3 was examined by Western
blotting in the ECC-1 and Ishikawa cells after exposure of GF for 24 hours at
the indicated concentrations (E, F). (* < 0.05).
Additional file 3: Figure S2. The effect of Galloflavin on cell cycle
progression in the ECC-1 and Ishikawa cells. The ECC-1(A) and Ishikawa
(B) were treated with the indicated doses of GF (1–50 uM) for 24 hours.
Cell cycle analysis was performed using Cellometer. GF minimally induced
cell cycle G1 phase arrest in ECC-1 cells, while Ishikawa exhibited
significant G2 phase arrest after GF treatment.
Additional file 4: Figure S3. The effect of Galloflavin on adhesion and
invasion in theECC-1 and Ishikawa cells. The ECC-1 (A) and Ishikawa (B)
cells were cultured for 24 hours and then treated with GF in laminin-1
coated 96 well plates or BME coated 96 transwell plates for 2 hours. GF
decreased adhesion and invasion in both cell lines. Western blotting
results demonstrated that GF decreased Slug protein expression and
increased E-cadherin expression after 24 hours of treatment (C, D). Each
experiment was performed three times. (* < 0.05).
Additional file 5: Figure S4. Galloflavin induced ROS generation and
mitochondrial DNA damage in the ECC-1 and Ishikawa cell lines. The cells
were treated with GF at different concentrations for 16 hours. The ROS
level was determined using DCFH-DA dye detected on a plate reader in
ECC-1 (A) and Ishikawa (B). ECC-1(C) and Ishikawa (D) cells were treated
with GF for 24 hours. Mitochondrial DNA damage was analyzed by qPCR
assay. (* < 0.05).
Additional file 6: Figure S5. Galloflavin inhibited glycolytic metabolism in
the endometrial cancer cells. The ECC-1and Ishikawa cells were treated with GF
for 2 hours. Glucose uptake was determined using the 2-NBDG assay (A). ATP
level, lactate, pyruvate and malate production were determined after treatment
of GF for 16 hours (B, C, D. E). Pyruvate dehydrogenase (PDH) and glutaminase
(GLS) protein expression were detected by Western blotting. Both PDH and
GLS protein expression were increased after 16 hours treatment (* < 0.05).
Additional file 7: Figure S6. Inhibition of c-Myc by JQ1 synergistically
increased sensitivity of Galloflavin. ECC-1 and Ishikawa cells were cultured for
24 hours and then treated with GF overnight. Western blotting demonstrated
that GF inhibited c-Myc protein expression (A). JQ1 synergistically increased the
sensitivity of GF after 72 hours treatment in ECC-1 (B), Ishikawa cells (C), SKOV3
(E) and KLE cells (F) (CI < 1). The effect of JQ1 and GF on c-Myc protein
expression was assessed by Western blotting in ECC-1, Ishikawa, SKOV3
and KLE cells (D, G).
Additional file 8: Figure S7. Postulated pathways by which Galloflavin
inhibits LDH activity. GF inhibited LDH activity by either competing for the
NADH bind site or inhibiting c-Myc protein expression, or a combination of
the two pathways.
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